Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Traditional Chinese medicine versus Zoloft for mild-to-moderate depression
ChiCTR-IPR-14005341Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sertraline and bazhengsan in major depressive disorder (MDD) (2 arms), sponsored by The Second Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoints: Hamilton Depression Rating Scale for Depression and Self-Rating Depression Scale. Started Sep 2014; status: recruiting.
02
Drugs
sertralinebazhengsan
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR-IPR-14005341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005341.